‘ZS-MDR-TB’ versus ‘ZR-MDR-TB’: improving treatment of MDR-TB by identifying pyrazinamide susceptibility

‘ZS-MDR-TB’ versus ‘ZR-MDR-TB’: improving treatment of MDR-TB by identifying pyrazinamide susceptibility

Indispensable for shortening treatment of drug-susceptible tuberculosis (TB), pyrazinamide (PZA, Z) is also essential in the treatment of multidrug-resistant (MDR)-TB. While resistance to PZA in MDR-TB is associated with poor treatment outcome, bacillary susceptibility to PZA along with the use of f...

Full description

Bibliographic Details
Main Authors: Ying Zhang, Kwok Chiu Chang, Chi-Chiu Leung, Wing Wai Yew, Brigitte Gicquel, Dorothy Fallows, Gilla Kaplan, Richard E Chaisson, Wenhong Zhang
Format: Article
Language:English
Published: Taylor & Francis Group 2012-07-01
Series:Emerging Microbes and Infections
Subjects:
MDR-TB
pncA
pyrazinamide
susceptibility testing
therapy
tuberculosis
Online Access:https://www.tandfonline.com/doi/10.1038/emi.2012.18

Internet

https://www.tandfonline.com/doi/10.1038/emi.2012.18

Similar Items